Although no studies have yet tested the effects of morusin on the pathogenesis of type II diabetes using relevant in vivo models (e.g., ob/ob, db/db mouse or HFD-fed mice), morusin may also exert anti-diabetes effects in this context, considering that morusin potentially regulates systemic ROS levels, lipogenesis, lipolysis, C/EBPβ and PPARγ signaling, arachidonic acid metabolism and ER-resident proteins implicated in ER stress [16,59,64], all of which have been frequently implicated in type II diabetes as well as type I diabetes [42,63,86,87]. This evidence concerns the gene PPARG and type 1 diabetes mellitus.